Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Livial 2.5mg tablets

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Tibolone may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Tibolone

Equivalent medicines (same active substance, strength and form)

Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

for Livial 2.5 mg tablet The active substance is: tibolone. This medicine is a hormone replacement therapy (HRT). It contains tibolone, a substance that has favourable effects on different tissues in the body, such as brain, vagina and bone. This medicine is used in postmenopausal women with at least 12 months (1 year) since their last natural period. This medicine is used for: Relief of symptoms occurring after menopause During the menopause, the amount of the oestrogen produced by a woman's body drops. This can cause symptoms such as hot face, neck and chest ("hot flushes"). Livial alleviates these symptoms after menopause. You will only be prescribed this medicine if your symptoms seriously hinder your daily life. Prevention of osteoporosis After the menopause some women may develop fragile bones (osteoporosis). You should discuss all available options with your doctor. If you are at an increased risk of fractures due to osteoporosis and other medicines are not suitable for you, you can use Livial to prevent osteoporosis after menopause. There are three different kinds of HRT:

  • Oestrogen-only HRT
  • Combined HRT, containing two kinds of female hormone, an oestrogen and a progestogen.
  • Livial, which contains a substance called tibolone Livial is different from other HRT. Instead of actual hormones (such as oestrogen and progestogen) it contains tibolone. Your body breaks down tibolone to make hormones. Its effects and benefits are similar to combined HRT. In section 6, 'Contents of the pack and other information' you can find more information about Livial and what it is used for.

What you need to know before you take it

e Livial For information on when you can start taking Livial, (including after a hysterectomy) see section 3.1 (overleaf). Medical History and regular check-ups The use of HRT or Livial carries risks that need to be considered when deciding whether to start taking it, or whether to carry on taking it. This is especially important if you are more than 60 years old. The experience in treating women with a premature menopause (due to ovarian failure or surgery) is limited. If you have a premature menopause the risks of using HRT or Livial may be different. Please talk to your doctor. Before you start taking or restart HRT or Livial Your doctor will ask about your own and your family's medical history. Your doctor may decide to perform a physical examination. This may include an examination of your breasts and /or an internal examination, if necessary. →Tell your doctor if you have any medical problems or illnesses. Regular check-ups Once you have started on Livial, you should see your doctor for regular check-ups (at least once a year). At these check-ups, discuss with your doctor the benefits and risks of continuing with Livial. Go for regular breast screening, as recommended by your doctor. Be sure to

  • go for regular breast screening and cervical smear tests
  • regularly check your breasts for any changes such as dimpling of the skin, changes in the nipple, or any lumps you can see or feel. 2.1 Some women should not take Livial Do not take Livial If any of the following applies to you. If you are not sure about any of the points below, talk to your doctor before taking Livial

• • • • • • • • • • • •

If you have or have ever had breast cancer, or if you are suspected of having it If you have cancer which is sensitive to oestrogens, such as cancer of the womb lining (endometrium), or if you are suspected of having it If you have any unexplained vaginal bleeding If you have excessive thickening of the womb lining (endometrial hyperplasia) that is not being treated. If you have or have ever had a blood clot in a vein (thrombosis), such as in the legs (deep venous thrombosis) or the lungs (pulmonary embolism) If you have a blood clotting disorder (such as protein C, protein S, or antithrombin deficiency) If you have or recently have had a disease caused by blood clots in the arteries, such as a heart attack, stroke or angina If you have or have ever had a liver disease and your liver function tests have not returned to normal If you have a rare blood problem called "porphyria" which is passed down in families (inherited) If you are allergic to tibolone or any of the other ingredients of this medicine (listed in section 6) If you are pregnant or think you might be pregnant. If you are breastfeeding.

If any of the above conditions appear for the first time while taking Livial, stop taking it at once and consult your doctor immediately. If you have started the menopause you should not take Livial until 12 months after your last natural period. If you take it sooner than this you may have irregular bleeding. 2.2 Warning and precautions Talk to your doctor, pharmacist or nurse before taking Livial. If you have ever had any of the following problems, tell your doctor before you start the treatment, as these may return or become worse during treatment with Livial. If so, you should see your doctor more often for check-ups:

  • fibroids inside your womb
  • growth of the womb lining outside your womb (endometriosis) or a history of excessive growth of the womb lining (endometrial hyperplasia)
  • increased risk of developing blood clots (see "Blood clots in a vein (thrombosis)")
  • increased risk of getting an oestrogen-sensitive cancer (such as having a mother, sister or grandmother who has had breast cancer)
  • high blood pressure
  • a liver disorder, such as a benign liver tumour
  • diabetes
  • gallstones
  • migraine or severe headaches
  • a disease of the immune system that affects many organs of the body (systemic lupus erythematosus, SLE)
  • epilepsy

• • • •

asthma a disease affecting the eardrum and hearing (otosclerosis) a very high level of fat in your blood (triglycerides) fluid retention due to cardiac or kidney problems

2.3 Stop taking Livial and see a doctor immediately If you notice any of the following when taking Livial:

  • any of the conditions mentioned in the "Do not take Livial" section
  • yellowing of your skin or the whites of your eyes (jaundice). These may be signs of a liver disease
  • a large rise in your blood pressure (symptoms may be headache, tiredness, dizziness)
  • migraine-like headaches which happen for the first time
  • if you become pregnant
  • if you notice signs of a blood clot, such as: − painful swelling and redness of the legs − sudden chest pain − difficulty in breathing For more information, see "Blood clots in a vein (thrombosis)". Note: Livial is not a contraceptive. If it is less than 12 months since your last menstrual period or you are under 50 years old, you may still need to use additional contraception to prevent pregnancy. Speak to your doctor for advice. 2.4 HRT and Cancer Excessive thickening of the lining of the womb (endometrial hyperplasia) and cancer of the lining of the womb (endometrial cancer) There have been reports of an increased cell growth or cancer of the lining of the womb in women using Livial. The risk of cancer of the lining of the womb increases the longer you take the medicine. Irregular bleeding You may have irregular bleeding or drops of blood (spotting) during the first 3-6 months of taking Livial. But if the bleeding or spotting:
  • Carries on for more than the first 6 months
  • Starts after you have been taking Livial for more than 6 months
  • Carries on even after you've stopped taking Livial →see your doctor as soon as possible. Breast cancer Evidence shows that taking tibolone increases the risk of breast cancer. The extra risk depends on how long you use tibolone. In studies with HRT, after stopping HRT the extra risk decreased with time, but the risk may persist for 10 years or more when women have used HRT for more than 5 years. No data for persistence of risk after stopping are available for tibolone, but a similar pattern cannot be ruled out.

Compare Women taking Livial have a lower risk than women using combined HRT and a comparable risk with oestrogen-only HRT. •

Regularly check your breasts. See your doctor if you notice any changes such as: o dimpling or sinking of the skin o changes in the nipple o any lumps you can see or feel

→Make an appointment to see your doctor as soon as possible Ovarian cancer Ovarian cancer is rare – much rarer than breast cancer. The use of oestrogen-only or combined oestrogen-progestagen HRT has been associated with a slightly increased risk of ovarian cancer. The risk of ovarian cancer varies with age. For example, in women aged 50 to 54 who are not taking HRT, about 2 women in 2000 will be diagnosed with ovarian cancer over a 5-year period. For women who have been taking HRT for 5 years, there will be about 3 cases per 2000 users (i.e. about 1 extra case). With use of Livial, the increased risk of ovarian cancer is similar to other types of HRT. 2.5 Effect of HRT on heart and circulation Blood clots in a vein (thrombosis) The risk of blood clots in the veins is about 1.3 to 3-times higher in HRT users than in non-users, especially during the first year of taking it. Blood clots can be serious, and if one travels to the lungs, it can cause chest pain, breathlessness, fainting or even death. You are more likely to get a blood clot in your veins as you get older and if any of the following applies to you. Inform your doctor if any of these situations apply to you:

  • you are pregnant or recently had a baby
  • you use oestrogens
  • you are unable to walk for a long time because of major surgery, injury or illness (see also section 3, If you need to have surgery)
  • you are seriously overweight (BMI >30 kg/m2)
  • you have any blood clotting problem that needs long-term treatment with a medicine used to prevent blood clots
  • if any of your close relatives has ever had a blood clot in the leg, lung or another organ
  • you have systemic lupus erythematosus (SLE)
  • you have cancer. For signs of a blood clot, see "Stop taking Livial and see a doctor immediately".

Compare Looking at women in their 50s who are not taking HRT, on average, over a 5 year period, 4 to 7 in 1000 would be expected to get a blood clot in a vein. For women in their 50s who have been taking oestrogen-progestogen HRT for over 5 years, there will be 9 to 12 cases in 1000 users (i.e. an extra 5 cases). With use of Livial, the increased risk of getting a blood clot in a vein is lower than with other types of HRT. Heart disease (heart attack) There is no evidence that HRT or Livial will prevent a heart attack. Women over the age of 60 who use oestrogen-progestogen HRT are slightly more likely to develop heart disease than those not taking any HRT. As the risk of heart disease strongly depends on age, the number of extra cases of heart disease due to use of oestrogen-progestogen HRT is very low in healthy women close to menopause, but will rise with more advanced age. There is no evidence to suggest that the risk of myocardial infarction with Livial is different to the risk of other HRT. Stroke Recent research suggests that HRT and Livial slightly increases the risk of having a stroke. The increased risk is seen mainly in women over 60 years old. Other things that can increase the risk of stroke include:

  • Getting older
  • High blood pressure
  • Smoking
  • Drinking too much alcohol
  • An irregular heartbeat If you are worried about any of these things, talk to your doctor to see if you should take HRT Compare Looking at women in their 50s who are not taking Livial – on average, over a 5-year period, 3 in 1000 would be expected to have a stroke. For women in their 50s who are taking Livial, the figure would be 7 in 1000 (i.e. an extra 4 cases). Looking at women in their 60s who are not taking Livial – on average, over a 5-year period, 11 in 1000 would be expected to have a stroke. For women in their 60s who are taking Livial, the figure would be 24 in 1000 (i.e. an extra 13 cases). 2.6 Other conditions HRT will not prevent memory loss. There is some evidence of a higher risk of memory loss in women who start using HRT after the age of 65. Speak to your doctor for advice. Livial is not intended for contraceptive use.

Treatment with Livial results in a marked dose-dependent decrease in HDL cholesterol (from 16.7% with a 1.25 mg dose to -21.8% for the 2.5 mg dose after 2 years). Total triglycerides and lipoprotein(a) levels were also reduced. The decrease in total cholesterol and VLDL-C levels was not dose-dependent. Levels of LDL-C were unchanged. The clinical implication of these findings is not yet known. Oestrogens may cause fluid retention, and therefore patients with cardiac or renal dysfunction should be carefully observed. Women with pre-existing hypertriglyceridaemia should be followed closely during oestrogen replacement or hormone replacement therapy, since rare cases of large increases of plasma triglycerides leading to pancreatitis have been reported with oestrogen therapy in this condition. Treatment with Livial results in a very minor decrease of thyroid binding globulin (TBG) and total T4. Levels of total T3 are unaltered. Livial decreases the level of sex-hormone-binding globulin (SHBG), whereas the levels of corticoid binding globulin (CBG) and circulating cortisol are unaffected. 2.7 Other medicines and Livial Some medicines may interfere with the effect of Livial. This might lead to irregular bleeding. This applies to the following medicines: • Medicines against blood clotting (such as warfarin) • Medicines for epilepsy (such as phenobarbital, phenytoin and carbamazepine) • Medicines for tuberculosis (such as rifampicin) • Herbal remedies containing St John's Wort (Hypericum perforatum). Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes medicines obtained without a prescription, herbal medicines or other natural products. 2.8 Having an Operation If you are going to have an operation, make sure your doctor knows about it. You may need to stop taking HRT about 4 to 6 weeks before the operation, to reduce the risk of a blood clot. Your doctor will tell you when you can start taking HRT again. 2.9 Livial with food and drink You can eat or drink normally while you are taking Livial. 2.10 Pregnancy and breast-feeding Livial is for use in postmenopausal women only. If you become pregnant, stop taking Livial and contact your doctor. If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. 2.11 Driving and using machines Livial has no known effect on the ability to drive or use machines.

2.12 Livial contains Lactose Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before using Livial. If you are worried about anything in this section, talk to your doctor about the risks and benefits of HRT.

How to take it

Livial 3.1 When can you start taking Livial? If it is not yet 12 months since your last natural period… If you are changing over from a period free HRT… (see note below)… If you have never used HRT before If you were prescribed HRT because you have had a hysterectomy… If you are being treated for endometriosis (a condition in which parts of the womb lining move around the body)… If you are changing over from another type of HRT with which you have periods… (see the note below)…

Wait before taking Livial (see section 2.1)…

Start taking Livial straight away

Wait for your next period. Start taking Livial as soon as your period ends

If you are changing over from another type of HRT There are several different types of HRT, such as tablets, patches and gels. Most contain either oestrogen, or oestrogen and progestogen. With some you still have periods, and with some you don't (these are called period-free HRT). 3.2 How to take Livial Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. The recommended dose is one tablet every day. Take this dose unless your doctor or pharmacist told you to do something different. Press the tablet so that it comes through the foil. Swallow the tablet with some water or other drink, without chewing. Take Livial at the same time each day. The strips of tablets are marked with the days of the week. Start by taking a tablet marked with the current day. For example, if it is Monday, take a tablet marked Monday on the top row of the

strip. Follow the arrows until the strip is empty. Start the next strip the next day. Do not leave a break between strips or packs. Your doctor will aim to prescribe the lowest dose to treat your symptoms for as short as necessary. Speak to your doctor if you think this dose is too strong or not strong enough. 3.3 If you take more Livial than you should It is unlikely that taking more than one tablet will do you any harm, but you may feel sick, be sick or have some vaginal bleeding. 3.4 If you forget to take Livial If you forget to take a tablet, take it as soon as you remember, unless you are more than 12 hours late. If you are more than 12 hours late, just skip it, and take your next tablet at the usual time. Don't take a double dose. 3.5 If you need to have surgery If you are going to have surgery, tell the surgeon that you are taking Livial. You may need to stop taking Livial about 4 to 6 weeks before the operation to reduce the risk of a blood clot (see section 2, 'Blood clots in a vein'). Ask your doctor when you can start taking Livial again. 4. Possible side effects The following diseases are reported more often in women using HRT compared to women not using HRT:

  • breast cancer
  • abnormal growth or cancer of the lining of the womb (endometrial hyperplasia or cancer)
  • ovarian cancer
  • blood clots in the veins of the legs or lungs (venous thromboembolism)
  • heart disease
  • stroke
  • probable memory loss if HRT is started over the age of 65 For more information about these side effects, see section 2. Like all medicines, this medicine can cause side effects, although not everybody gets them. Most side effects are mild. →Tell your doctor or pharmacist if you are worried about any side effects which you think may be due to Livial. (see also section 2.3, 'Stop taking Livial and see a doctor immediately') 4.1 Serious side effects – see a doctor straight away If you think you may have signs of a serious side effect, see a doctor straight away. You may need to stop taking Livial:
  • If your blood pressure rises
  • If your skin or the whites of your eyes go yellow (jaundice)
  • If you suddenly have migraine-type headaches (see section 2.5 above)
  • If you have signs of a blood clot (see section 2.5 above)
  • If you get any of the problems listed in section 2.1 (Do not take Livial)

4.2 Other side effects Common (may affect up to 1 in 10 women):

  • breast pain
  • stomach or pelvic pain
  • unusual hair growth
  • vaginal bleeding or spotting. This is usually nothing to worry about in the first few months of taking HRT. If bleeding continues, or starts after you have been on HRT for a while see section 2.4.
  • vaginal problems such as more secretions, itching, irritation and thrush
  • thickening of the lining of the womb or the lining of the cervix
  • weight gain. Uncommon (may affect up to 1 in 100 women):
  • swollen hands, ankles or feet – a sign of fluid retention
  • stomach upset
  • acne
  • painful nipples or breasts feeling uncomfortable
  • vaginal infections Rare (may affect up to 1 in 1000 women):
  • itchy skin Some women taking Livial have also reported:
  • depression, dizziness, headache
  • joint pain or muscle pain
  • skin problems such as rash or itching
  • loss of vision or blurred vision
  • changes in liver tests There have been reports of breast cancer and of an increased cell growth or cancer of the lining of the womb in women using Livial. →Tell your doctor if any of the above mentioned side effects continues or becomes troublesome. The following side effects have been reported with other HRTs:
  • gall bladder disease
  • various skin disorders: − discolouration of the skin especially of the face or neck known as "pregnancy patches" (chloasma) − painful reddish skin nodules (erythema nodosum) − rash with target-shaped reddening or sores (erythema multiforme) Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible

Possible side effects

not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple app Store. By reporting side effects you can help provide more information on the safety of this medicine.

How to store it

Livial Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton after 'EXP'. The expiry date refers to the last day of that month. Store below 25°C. Do not refrigerate. Store in the original package. Keep the blister in the outer carton, in order to protect from light and moisture. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

Contents of the pack and other information

What Livial contains The active substance is tibolone. The other ingredients are potato starch, lactose monohydrate, ascorbyl palmitate and magnesium stearate. What Livial looks like and the contents of the pack Livial tablets are white, and marked Organon* on one side, and "MK2" on the other side. They come in packs of one or three strips of 28 tablets. The Marketing Authorisation Holder is: Organon Pharma (UK) Limited, Shotton Lane, Cramlington, United Kingdom, NE23 3JU. The Manufacturer is: NV Organon, PO Box 20, 5340 BH Oss Netherlands This leaflet was last revised in September 2024. More about Livial The most important natural sex hormones in women are oestrogens and progesterone. These hormones are produced in the ovaries. They are needed for normal sexual development and control the menstrual cycle. The menopause is the time (usually around the age of 50) when the ovaries gradually stop producing oestrogens. If the ovaries are removed surgically before the menopause, the decrease in hormone production occurs very quickly. The decrease in hormone production often leads to symptoms such as hot flushes and night sweats. The shortage of sex hormones may also cause the lining of the vagina to become thin and dry. So sexual intercourse may be painful and vaginal infections may occur more frequently. Some women also experience mood changes, nervousness, depression, irritability and loss of sexual desire.

Oestrogens are also important for bone formation. Bone is built up during youth, and peak bone mass is reached between the age of 20 and 30. After that, bone mass decreases, at first slowly, but later in life more quickly, especially after the menopause. Gradually, the bones become brittle and may easily break (osteoporosis), especially in your spine, hip and wrists. Osteoporosis may also cause back pain, loss of height and a curved back. Livial contains tibolone, a substance that has beneficial effects on different tissues in the body, such as the brain, vagina and bone. This results in the relief of symptoms such as hot flushes and night sweats, and an improvement in the lining of the vagina, mood and sexual desire. Livial can also stop the process of bone loss that occurs in your spine, hip and wrists after the menopause. Unlike some hormone replacement therapies, Livial does not stimulate the lining of the womb. So treatment with Livial does not cause monthly vaginal bleeding. To listen to or request a copy of this leaflet in Braille, large print or audio please call, free of charge: 0800 198 5000 (UK only) Please be ready to give the following information: Product name: Livial 2.5mg tablets Reference number: PL 00025/0599 This is a service provided by the Royal National Institute for Blind People. © 2024 Organon group of companies. All rights reserved. PIL.LIV.24.UK.0370.IA-MAH_Cram.NoRCN

Frequently asked questions about Livial 2.5mg tablets

How do I take Livial 2.5mg tablets?

Livial 2.5mg tablets comes as tablet containing 2.5mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in Livial 2.5mg tablets?

The active substance in Livial 2.5mg tablets is tibolone.

Are there equivalent medicines to Livial 2.5mg tablets?

Medicines with the same active substance, strength and form include: Tibolone 2.5 mg Tablets, Tibolone 2.5 mg tablets, Tibolone 2.5 mg tablets. They are interchangeable only if your prescriber or pharmacist says so.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Livial 2.5mg tablets, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Livial 2.5mg tablets without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Tibolone (4 medicines)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

• Treatment of oestrogen deficiency symptoms in postmenopausal women, more than one year after menopause.

• Prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis. (See also section 5.1.)

For all women the decision to prescribe Livial should be based on an assessment of the individual patient's overall risks and, particularly in the over 60s, should include consideration of the risk of stroke (see sections 4.4 and 4.8).

4.2. Posology and method of administration

Posology

The dosage is one tablet per day. The tablets should be swallowed with some water or other drink, preferably at the same time every day.

For initiation and continuation of treatment of postmenopausal symptoms, the lowest effective dose for the shortest duration (see also section 4.4) should be used.

A separate progestogen should not be added with Livial treatment.

Starting Livial

Women experiencing a natural menopause should commence treatment with Livial at least 12 months after their last natural bleed. In case of a surgical menopause, treatment with Livial may commence immediately.

Women being treated with gonadotrophin releasing hormone (GnRH) analogues, for example, for endometriosis, may commence treatment with Livial immediately.

Any irregular/unscheduled vaginal bleeding, either on or off HRT, should be investigated to exclude malignancy before starting Livial (see section 4.3).

Switching from a sequential or continuous combined HRT preparation

If changing from a sequential HRT preparation, treatment with Livial should start the day following completion of the prior regimen. If changing from a continuous-combined HRT preparation, treatment can start at any time.

Missed dose

A missed dose should be taken as soon as remembered, unless it is more than 12 hours overdue. In the latter case, the missed dose should be skipped and the next dose should be taken at the normal time. Missing a dose may increase the likelihood of breakthrough bleeding and spotting.

Older people

No dose adjustment is necessary for the elderly.

Paediatric population

There is no relevant use of Lival in the paediatric population.

Method of administration

Oral use.

4.3. Contraindications

• Pregnancy and lactation

• Known, past or suspected breast cancer – Livial increased the risk of breast cancer recurrence in a placebo controlled trial

• Known or suspected oestrogen-dependent malignant tumours (e.g. endometrial cancer)

• Undiagnosed genital bleeding

• Untreated endometrial hyperplasia

• Previous or current venous thromboembolism (deep venous thrombosis, pulmonary embolism)

• Known thrombophilic disorders (e.g. protein C, protein S, or antithrombin deficiency, see section 4.4)

• Any history of arterial thromboembolic disease (e.g. angina, myocardial infarction, stroke or TIA)

• Acute liver disease, or a history of liver disease as long as liver function tests have failed to return to normal

• Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1.

• Porphyria

4.4. Special warnings and precautions for use

For the treatment of postmenopausal symptoms, Livial should only be initiated for symptoms that adversely affect quality of life. In all cases, a careful appraisal of the risks and benefits should be undertaken at least annually and Livial should only be continued as long as the benefit outweighs the risk.

The risks of stroke, breast cancer and, in women with an intact uterus, endometrial cancer (see below and section 4.8) for each woman should be carefully assessed, in the light of her individual risk factors and bearing in mind the frequency and characteristics of both cancers and stroke, in terms of their response to treatment, morbidity and mortality.

Evidence regarding the risks associated with HRT or tibolone in the treatment of premature menopause is limited. Due to the low level of absolute risk in younger women, however, the balance of benefits and risks for these women may be more favourable than in older women.

Medical examination/follow-up

Before initiating or reinstituting HRT or tibolone, a complete personal and family medical history should be taken. Physical (including pelvic and breast) examination should be guided by this and by the contraindications and warnings for use.

• During treatment, periodic check-ups are recommended of a frequency and nature adapted to the individual woman. Women should be advised what changes in their breasts should be reported to their doctor or nurse (see 'Breast cancer' below). Investigations, including appropriate imaging tools, e.g. mammography, should be carried out in accordance with currently accepted screening practices, modified to the clinical needs of the individual.

Conditions which need supervision

• If any of the following conditions are present, have occurred previously, and/or have been aggravated during pregnancy or previous hormone treatment, the patient should be closely supervised. It should be taken into account that these conditions may recur or be aggravated during treatment with Livial, in particular:

-

Leiomyoma (uterine fibroids) or endometriosis

-

Risk factors for thromboembolic disorders (see below)

-

Risk factors for oestrogen dependent tumours, e.g. 1st degree heredity for breast cancer

-

Hypertension

-

Liver disorders (e.g. liver adenoma)

-

Diabetes mellitus with or without vascular involvement

-

Cholelithiasis

-

Migraine or (severe) headache

-

Systemic lupus erythematosis

-

A history of endometrial hyperplasia (see below)

-

Epilepsy

-

Asthma

-

Otosclerosis

Reasons for immediate withdrawal of therapy:

Therapy should be discontinued in case a contraindication is discovered and in the following situations:

• Jaundice or deterioration in liver function

• Significant increase in blood pressure

• New onset of migraine-type headache

Endometrial hyperplasia and carcinoma

• The available data from randomised controlled trials are conflicting; however, observational studies have consistently shown that women who are prescribed Livial in normal clinical practice are at an increased risk of having endometrial cancer diagnosed (see also section 4.8). In these studies risk increased with increasing duration of use. Tibolone increases endometrial wall thickness, as measured by transvaginal ultrasound.

• Break-through bleeding and spotting may occur during the first months of treatment (see section 5.1). Women should be advised to report any break-through bleeding or spotting if it is still present after 6 months of treatment, if it starts beyond that time or if it continues after treatment has been discontinued. The woman should be referred for gynaecological investigation, which is likely to include endometrial biopsy to exclude endometrial malignancy.

Breast cancer

• A meta-analysis of epidemiological studies, including the Million Women Study (MWS), showed a significant increase in the risk of breast cancer in association with use of the 2.5 mg dose. This risk became apparent within 3 years of use and increased with duration of intake, see section 4.8. After stopping treatment, the excess risk will decrease with time and the time needed to return to baseline depends on the duration of prior HRT use. When HRT was taken for more than 5 years, the risk may persist for 10 years or more.

No data for persistence of risk after stopping are available for tibolone, but a similar pattern cannot be ruled out.

Ovarian cancer

Ovarian cancer is much rarer than breast cancer.

Epidemiological evidence from a large meta-analysis suggests a slightly increased risk in women taking oestrogen-only or combined oestrogen-progestagen HRT, which becomes apparent within 5 years of use and diminishes over time after stopping.

Some other studies including the Women's Health Initiative (WHI) trial suggest that the use of combined HRTs may be associated with a similar, or slightly smaller risk (see section 4.8).

In the Million Women Study it was shown that the relative risk for ovarian cancer with use of tibolone was similar to the risk associated with use of other types of HRT.

Venous thromboembolism

• Oestrogen or oestrogen-progestogen HRT is associated with a 1.3-3 fold risk of developing venous thromboembolism (VTE), i.e. deep vein thrombosis or pulmonary embolism. The occurrence of such an event is more likely in the first year of HRT than later (see section 4.8). In an epidemiological study using a UK database, the risk of VTE in association with tibolone was lower than the risk associated with conventional HRT, but only a small proportion of women were current users of tibolone and a small increase in risk compared with non-use cannot be excluded.

• Patients with known thrombophilic states have an increased risk of VTE and HRT or tibolone may add to this risk. HRT is therefore contraindicated in these patients (see section 4.3).

• Generally recognised risk factors for VTE include use of oestrogens, older age, major surgery, prolonged immobilisation, obesity (BMI > 30 kg/m2), pregnancy/postpartum period, systemic lupus erythematosus (SLE), and cancer. There is no consensus about the possible role of varicose veins in VTE. As in all postoperative patients, prophylactic measures need to be considered to prevent VTE following surgery. If prolonged immobilisation is to follow elective surgery temporarily stopping HRT or tibolone 4 to 6 weeks earlier is recommended, if possible. Treatment should not be restarted until the woman is completely mobilised.

• In women with no personal history of VTE but with a first degree relative with a history of thrombosis at young age, screening may be offered after careful counselling regarding its limitations (only a proportion of thrombophilic defects are identified by screening). If a thrombophilic defect is identified which segregates with thrombosis in family members or if the defect is 'severe' (e.g, antithrombin, protein S, or protein C deficiencies or a combination of defects) HRT or tibolone is contraindicated.

• Women already on anticoagulant treatment require careful consideration of the benefit-risk of use of HRT or tibolone.

• If VTE develops after initiating therapy, the drug should be discontinued. Patients should be told to contact their doctors immediately when they are aware of a potential thromboembolic symptom (e.g. painful swelling of a leg, sudden pain in the chest, dyspnea).

Coronary artery disease (CAD)

There is no evidence from randomised controlled trials of protection against myocardial infarction in women with or without existing CAD who received combined oestrogen-progestogen or oestrogen-only HRT. In an epidemiological study using the GPRD no evidence was found of protection against myocardial infarction in postmenopausal women who received tibolone.

Ischaemic stroke

• Tibolone increases the risk of ischaemic stroke from the first year of treatment (see section 4.8). The baseline risk of stroke is strongly age-dependent and so the effect of tibolone is greater with older age.

Other conditions

• Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

• Livial is not intended for contraceptive use.

• Treatment with Livial results in a marked dose-dependent decrease in HDL cholesterol (from -16.7% with a 1.25 mg dose to -21.8% for the 2.5 mg dose after 2 years). Total triglycerides and lipoprotein(a) levels were also reduced. The decrease in total cholesterol and VLDL-C levels was not dose-dependent. Levels of LDL-C were unchanged. The clinical implication of these findings is not yet known.

• Oestrogens may cause fluid retention, and therefore patients with cardiac or renal dysfunction should be carefully observed.

• Women with pre-existing hypertriglyceridaemia should be followed closely during oestrogen replacement or hormone replacement therapy, since rare cases of large increases of plasma triglycerides leading to pancreatitis have been reported with oestrogen therapy in this condition.

• Treatment with Livial results in a very minor decrease of thyroid binding globulin (TBG) and total T4. Levels of total T3 are unaltered. Livial decreases the level of sex-hormone-binding globulin (SHBG), whereas the levels of corticoid binding globulin (CBG) and circulating cortisol are unaffected.

• HRT does not improve cognitive function. There is some evidence of increased risk of probable dementia in women who start using continuous combined or oestrogen-only HRT after the age of 65.

4.5. Interaction with other medicinal products and other forms of interaction

Since Livial may increase blood fibrinolytic activity, it may enhance the effect of anticoagulants. This effect has been demonstrated with warfarin. Caution should therefore be exercised during the simultaneous use of Livial and anticoagulants, especially when starting or stopping concurrent Livial treatment. If necessary, the dose of warfarin should be adjusted.

There is limited information regarding pharmacokinetic interactions with tibolone An in vivo study showed that simultaneous treatment of tibolone affects pharmacokinetics of the cytochrome P450 3A4 substrate midazolam to a moderate extent. Based on this, drug interactions with other CYP3A4 substrates might be expected.

Compounds that induce CYP3A4 activity such as barbiturates, carbamazepine, hydantoins and rifampicin may enhance the metabolism of tibolone and thus affect its therapeutic effect.

Herbal preparations containing St.John's wort (Hypericum Perforatum) may induce the metabolism of oestrogens and progestogens via CYP3A4. Clinically, an increased metabolism of oestrogens and progestogens may lead to decreased effect and changes in the uterine bleeding profile.

4.6. Fertility, pregnancy and lactation

Pregnancy

Livial is contraindicated during pregnancy (see section 4.3). If pregnancy occurs during medication with Livial, treatment should be withdrawn immediately. For Livial no clinical data on exposed pregnancies are available.

Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown.

Breast-feeding

Livial is contraindicated during breast-feeding (see section 4.3).

Fertility

In animal studies, Livial had anti-fertility activities by virtue of its hormonal properties.

4.7. Effects on ability to drive and use machines

Livial is not known to have any effects on alertness and concentration.

4.8. Undesirable effects

This section describes undesirable effects, which were registered in 21 placebo-controlled studies (including the LIFT study), with 4,079 women receiving therapeutic doses (1.25 or 2.5 mg) of Livial and 3,476 women receiving placebo. The duration of treatment in these studies ranged from 2 months to 4.5 years. Table 1 shows the undesirable effects that occurred statistically significantly more frequently during treatment with Livial than with placebo.

Table 1 Undesirable effects of Livial

System organ class

Common>1%,<10%

Uncommon>0.1%,<1%

Rare

>0.01%,<0.1%

Metabolism and nutrition disorders

Oedema**

Gastrointestinal disorders

Lower abdominal pain

Abdominal discomfort**

Skin and subcutaneous tissue disorders

Abnormal hair growth

Acne

Pruritus**

Reproductive system and breast disorders

Vaginal discharge

Endometrial wall thickening

Postmenopausal haemorrhage

Breast tenderness

Genital pruritus

Vaginal candidiasis

Vaginal haemorrhage

Pelvic pain

Cervical dysplasia

Genital discharge

Vulvovaginitis

Breast discomfort

Fungal infection

Vaginal mycosis

Nipple pain

Investigations

Weight increase

Abnormal cervical smear*

* The majority consisted of benign changes. Cervix pathology (cervical carcinoma) was not increased with Livial compared to placebo.

** These adverse reactions were identified through post-marketing surveillance. The frequency category was estimated based on relevant clinical trials.

In market use, other undesirable effects that have been observed include:

dizziness, rash, seborrheic dermatosis, headache, migraine, visual disturbances (including blurred vision), depression, effects on the musculoskeletal system such as arthralgia or myalgia and changes in liver function parameters.

Breast cancer

• An up to 2-fold increased risk of having breast cancer diagnosed is reported in women taking combined oestrogen-progestogen therapy for more than 5 years.

The increased risk in users of oestrogen-only and tibolone therapy is lower than seen in users of oestrogen-progestogen combinations

•

The level of risk is dependent on the duration of use (see section 4.4).

•

Results of the largest epidemiological study (MWS) are presented.

Table 2 Million Women study – Estimated additional risk of breast cancer after 5 years' use

Endometrial cancer risk

Postmenopausal women with a uterus

The endometrial cancer risk is about 5 in every 1,000 women with a uterus not using HRT or tibolone.

The randomised placebo controlled trial that included women who had not been screened for endometrial abnormalities at baseline, and therefore reflected clinical practice, identified the highest risk of endometrial cancer, (LIFT study, mean age 68 years). In this study, no cases of endometrial cancer were diagnosed in the placebo group (n=1,773) after 2.9 years compared with 4 cases of endometrial cancer in the Livial group (n=1,746). This corresponds to a diagnosis of 0.8 additional case of endometrial cancer in every 1,000 women who used Livial for one year in this study (see section 4.4).

Risk of ischaemic stroke

• The relative risk of ischaemic stroke is not dependent on age or on duration of use, but as the baseline risk is strongly age-dependent, the overall risk of ischaemic stroke in women who use HRT or tibolone will increase with age, see section 4.4.

• A 2.9 year randomised controlled study has estimated a 2.2-fold increase in the risk of stroke in women (mean age 68 years) who used 1.25 mg Livial (28/2,249) compared with placebo (13/2,257). The majority (80%) of strokes were ischaemic.

• The baseline risk of stroke is strongly age-dependent. Thus, the baseline incidence over a 5 year period is estimated to be 3 per 1,000 women aged 50-59 years and 11 per 1,000 women aged 60-69 years.

• For women who use Livial for 5 years, the number of additional cases would be expected to be about 4 per 1000 users aged 50-59 years and 13 per 1,000 users aged 60-69 years.

Other adverse reactions have been reported in association with oestrogen and oestrogen-progestogen treatment:

- Ovarian cancer

Use of estrogen-only or combined oestrogen-progestogen HRT has been associated with a slightly increased risk of having ovarian cancer diagnosed (see section 4.4).

A meta-analysis from 52 epidemiological studies reported an increased risk of ovarian cancer in women currently using HRT compared to women who have never used HRT (RR 1.43, 95% CI 1.31-1.56). For women aged 50 to 54 years taking 5 years of HRT, this results in about 1 extra case per 2,000 users. In women aged 50 to 54 who are not taking HRT, about 2 women in 2,000 will be diagnosed with ovarian cancer over a 5-year period.

In the Million Women Study, taking 5 years of tibolone resulted in 1 extra case per 2,500 users (see section 4.4).

- HRT is associated with a 1.3-3-fold increased relative risk of developing venous thromboembolism (VTE), i.e. deepvein thrombosis or pulmonary embolism. The occurrence of such an event is more likely in the first year of using HRT (see section 4.4). Results of the WHI studies are presented:

- The risk of coronary artery disease is slightly increased in users of combined oestrogen-progestogen HRT over the age of 60 (see section 4.4). There is no evidence to suggest that the risk of myocardial infarction with tibolone is different to the risk with other HRT.

Table 4 WHI Studies combined - Additional risk of ischaemic stroke over 5 years' use

Age range (years)

Incidence per 1000 women in placebo arm over 5 years

Risk ratio and 95%CI

Additional cases per 1000 HRT users over 5 yers

50-59

8

1.3 (1.1-1.6)

3 (1-5)

- Gall bladder disease

- Skin and subcutaneous disorders: chloasma, erythema multiforme, erythema nodosum, vascular purpura

- Probable dementia over the age of 65 (see section 4.4)

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9. Overdose

The acute toxicity of tibolone in animals is very low. Therefore, toxic symptoms are not expected to occur, even when several tablets are taken simultaneously. In cases of acute overdose, nausea, vomiting and vaginal bleeding in females may occur. No specific antidote is known. Symptomatic treatment can be given if necessary.

💬 Ask about this leaflet

Ask anything about Livial 2.5mg tablets. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Medicines containing Tibolone

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →